

# Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency

MEI DENG<sup>1</sup>, MAN MAO<sup>2</sup>, LI GUO<sup>1</sup>, FENG-PING CHEN<sup>2</sup>, WANG-RONG WEN<sup>2</sup> and YUAN-ZONG SONG<sup>1</sup>

Departments of <sup>1</sup>Pediatrics and <sup>2</sup>Laboratory Science, The First Affiliated Hospital,  
Jinan University, Guangzhou, Guangdong 510630, P.R. China

Received June 6, 2015; Accepted September 6, 2016

DOI: 10.3892/etm.2016.3752

**Abstract.** The human solute carrier family 10 member 1 (SLC10A1) gene encodes sodium taurocholate cotransporting polypeptide (NTCP), the principal transporter of conjugated bile salts from the plasma into hepatocytes. Although the function of NTCP has been studied extensively and a number of SLC10A1 variations have been identified in humans, information regarding NTCP deficiency is limited. To date, only one patient with NTCP deficiency has been described; however, in the present study a pediatric patient who experienced intractable and striking hypercholanemia is presented. Analysis of the SLC10A1 gene in the patient revealed a homozygous p.Ser267Phe (c.800C>T) variation, which proved to be a single-nucleotide polymorphism (SNP) in the allele frequency of 4.7% of healthy controls. This variation involved a conserved amino acid residue on the orthologous alignment that was predicted to be 'disease-causing' by functional analysis using a number of bioinformatic tools. Next generation sequencing was performed; however, no other genetic causes were identified that would affect the bile acid homeostasis in the patient. Moreover, an adult, with the same genotype as the pediatric patient, was identified for the first time as experiencing mild hypercholanemia. The molecular and clinical findings in the present study suggest, for the first time, that there is an association between p.Ser267Phe SNP

and hypercholanemia, and this information may be used to clinically identify NTCP deficiency worldwide.

## Introduction

The human sodium taurocholate cotransporting polypeptide (NTCP) was cloned, localized and functionally characterized in the year 1994 (1). NTCP is encoded by the solute carrier family 10 member 1 (SLC10A1) gene and serves a key role in the enterohepatic circulation of bile salts, acting as the primary transporter of conjugated bile salts from the plasma into hepatocytes (2,3). Although the function of NTCP has been extensively studied and a number of SLC10A1 genetic variations have been identified in humans (4-6), the understanding of NTCP deficiencies remains limited. To date, only one patient with NTCP deficiency has been diagnosed (7); this patient was a pediatric patient with the homozygous and pathogenic p.R252H mutation in the SLC10A1 gene, clinically characterized by marked conjugated hypercholanemia and otherwise unremarkable manifestations. The diagnosis of this child patient with NTCP deficiency clearly established a primary role for NTCP in hepatic bile acid clearance and advances our understanding of normal physiology and the disease (8). However, to the best of our knowledge, no adult patient with NTCP deficiency has been diagnosed yet so far worldwide.

In the present study, the clinical and molecular findings of a second child with NTCP deficiency are described, and an adult with the same genotype and similar, but mild, biochemical alterations are diagnosed as the first adult case of NTCP deficiency.

## Materials and methods

**Subjects and ethical approval.** A six-month-old male infant, suspected to have NTCP deficiency, and his parents participated in the present study in the First Affiliated Hospital of Jinan University (Guangzhou, China). Clinical data were collected from the child and analyzed. Blood samples from 75 healthy volunteers (with a total of 150 SLC10A1 alleles) were collected for allele frequency analysis of the SLC10A1 variation identified in the patient.

The current study was approved by the Committee for Medical Ethics (The First Affiliated Hospital, Jinan University,

---

*Correspondence to:* Professor Yuan-Zong Song, Department of Pediatrics, The First Affiliated Hospital, Jinan University, 613 Huangpu Da Dao Xi, Guangzhou, Guangdong 501630, P.R. China  
E-mail: songyuanzong@vip.tom.com

**Abbreviations:** NTCP, sodium taurocholate cotransporting polypeptide; RFLP, restriction fragment length polymorphism; SNP, single nucleotide polymorphism; NGS, next generation sequencing; MAF, minor allele frequency; SVs, structural variations; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; TBA, total bile acids

**Key words:** sodium taurocholate cotransporting polypeptide, cholestasis, solute carrier family 10 member 1 gene, hypercholanemia, dysfunctional polymorphism

Table I. Polymerase chain reaction primers and conditions for solute carrier family 10 member 1 gene sequencing.

Exon	NTCP primer sequence	AT (°C)	Polymerase	Product (bp)
1	Forward 5'-GAACTAAGGAATCAAGAGCGGAGC-3' Reverse 5'-CAGGAATTTGAGGTGCTCATTTGG-3'	56	Taq	1,248
2	Forward 5'-CTTACTACCTTGTGCGACTTTGAG-3' Reverse 5'-GGAATTGGATCTTGTTTCTCTCG-3'	56	Taq	987
3-4	Forward 5'-GTACAAAATGTGGTAGCCTATGGAG-3' Reverse 5'-GTTCTCTGGTCTGTCTTGAGGTTTC-3'	56	LA-Taq	3,682
5	Forward 5'-CGAAGTTAGAAGTGAAGTGATGATGAAG-3' Reverse 5'-CTGTGTTTCTCGTTTTGGTGTGG-3'	58	Taq	1,432

AT, annealing temperature; bp, base pairs; NTCP, sodium taurocholate cotransporting polypeptide.

Guangzhou, China). Written informed consent was obtained from the parents of the child and from each healthy volunteer.

**SLC10A1 gene analysis.** To identify mutations in the SLC10A1 gene of the patient, each of the 5 exons and their flanking sequences, including the 5'- and 3'-untranslated regions and 309 base pairs upstream of the transcriptional start site, were amplified by polymerase chain reaction (PCR) using the primers and polymerases listed in Table I. All PCR amplification was conducted using a Mastercycler nexus PCR instrument (Eppendorf Instrumente GmbH, Hamburg, Germany). SLC25A13 exons 1, 2 and 5 were amplified using a PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) in a 50- $\mu$ l mixture that consisted of 0.25  $\mu$ l Taq (5 U/ $\mu$ l), 5  $\mu$ l 10X Buffer (Mg<sup>2+</sup> Plus), 1  $\mu$ l genomic DNA, 4  $\mu$ l dNTP Mixture (2.5 mM) and 37.75  $\mu$ l PCR-grade water, besides the relevant primer pair (1  $\mu$ l of each primer in 20  $\mu$ M). For the LA-PCR amplification of exons 3 and 4, the components of the reaction mixture was the same as above but the primer pair and a LA-Taq (Takara Biotechnology Co., Ltd.) instead of the polymerase Taq. The products were purified using a gel extraction kit (Omega Bio-Tek, Inc., Norcross, GA, USA), and analyzed using the Sanger sequencing on a 96-capillary ABI 3730xl DNA Analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Foster City, CA, USA) with a BigDye Terminator v 3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer's instructions.

**PCR-restriction fragment length polymorphism (PCR-RFLP) and variation screening.** A novel PCR-RFLP procedure was developed for the present study in order to confirm the genotypes of the patients family and to screen for variation between the 75 healthy volunteers. The nucleotide sequences of the forward and reverse primers used in PCR were 5'-CCA GTTCCCTCTGAGTGTATGTG-3' and 5'-GCAGGCTCA GGTCTAATATTGG-3', respectively (Invitrogen; Thermo Fisher Scientific, Inc.). The *Hph*I restriction enzyme was used (Thermo Fisher Scientific, Inc.). The PCR temperature profile was 94°C for 5 min, followed by 35 cycles of 94°C for 30 sec, 60°C for 40 sec, 72°C for 30 sec, then 72°C for 10 min. To calculate the variation frequency, the number of alleles bearing the variation in control subjects was divided by 150 then multiplied by 100.

**Alignment of homologous peptides.** The peptide identification and amino acid sequences were collected from the orthologue list of the human SLC10A1 gene in the Ensembl Genome Browser ([www.ensembl.org](http://www.ensembl.org)). The amino acid sequences of 40 homologous peptides in a diversity of species were aligned using BLAST/BLAT Ensembl software (<http://asia.ensembl.org/Multi/Tools/Blast?db=core>). Species included primates (human NTCP-1 and apical sodium-dependent bile acid transporter, gorilla, orangutan, olive baboon, gibbon, chimpanzee, macaque, marmoset, vervet African green money and bushbaby), rodents (opossum, rat, mouse and squirrel), laurasiatheria (ferret, armadillo, megabat and microbat), placental mammals (elephant, panda, horse, cow, sheep, alpaca, sloth, tree shrew, pig, dog, cat, shrew and dolphin), sauropsida (duck, chicken, flycatcher, softshell turtle and turkey), fish (cave fish and zebrafish) and invertebrate marine chordate (*Ciona intestinalis*).

**In silico prediction of pathogenicity.** PolyPhen-2, MutationTaster and SIFT were used to predict the pathogenicity of the SLC10A1 variation identified in the patient. PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) analysis identifies variation as 'probably damaging' if the probability is >0.85, and identifies the variation as 'possibly damaging' if the probability is >0.15 (9). MutationTaster (<http://mutationtaster.org/MutationTaster/index.html>) prediction identifies probabilities ~1 as a 'high security' of the prediction (10). SIFT ([http://sift.jcvi.org/www/SIFT\\_chr\\_coords\\_submit.html](http://sift.jcvi.org/www/SIFT_chr_coords_submit.html)) identifies the variation as being 'deleterious' if the SIFT score is <0.05 (11).

**Whole genome sequencing.** To eliminate the possibility of other genetic causes resulting in hypercholanemia in the patient, whole genome sequencing was performed using next generation sequencing (NGS). Genomic DNA from the patient was extracted from 2 ml peripheral blood. For quality-control, DNA concentrations were tested with a Nanodrop Spectrophotometer (Thermo Fisher Scientific, Inc.). Following quality-control measurements, the DNA was randomly fragmented into sections of 200-300 base pairs by using an ultrasonicator (Covaris, Inc., Woburn, MA, USA), then fragments of the desired length were purified and separated using gel electrophoresis in a 2% agarose gel, purified with a QIAquick PCR Purification Kit (QIAGEN, Suzhou, Jiangsu,

China), added into End Repair Mix (New England Biolabs, Inc., Ipswich, MA, USA), and incubated at 20°C for 30 min. The end-repaired DNA was purified with a QIAquick PCR Purification Kit (QIAGEN), then added to an A-Tailing Mix (New England Biolabs, Inc.), and incubated at 37°C for 30 min. Then, a ligation reaction was conducted by incubating the purified Adenylate 3' Ends DNA, Adapter and Ligation Mix (New England Biolabs, Inc.) at 20°C for 15 min. Adapter-ligated DNA was selected by running a 2% agarose gel and purified with a QIAquick Gel Extraction kit (QIAGEN). Following that, several rounds of PCR amplification were performed using a PCR Primer Cocktail and PCR Master Mix (New England Biolabs, Inc.) to enrich the Adapter-ligated DNA fragments. Then the PCR products were selected by running another 2% agarose gel and purified with a QIAquick Gel Extraction kit (QIAGEN). Adapter ligation and DNA cluster preparation were performed and the DNA fragments were analyzed using the Illumina HiSeq 2000 Sequencing System (Illumina, Inc., San Diego, CA, USA). A total of 95.92 G clean databases were generated for the DNA library that was constructed for the DNA sample. To ensure high quality analysis, the adapter pollutions and the reads which contained  $\geq 50\%$  low quality bases (quality value,  $\leq 5$ ) were removed, ensuring that the Q20 base rate of each lane was  $>93.77\%$ . The sequencing reads were aligned onto the reference genome sequence using the Short Oligonucleotide Analysis Package aligner/soap2 (<http://soap.genomics.org.cn/soapaligner.html>; BGI, Shenzhen, China) and single nucleotide polymorphisms (SNPs), InDels and structure variations (SVs) of the sequenced genome were analyzed, as described below.

To annotate and prioritize variation within the gene, common intronic variants were removed following comparison with those in the Single Nucleotide Polymorphism Database and the 1000 Genomes Project (National Center for Biotechnology Information, Bethesda, MD, USA). Synonymous and non-synonymous mutations in exons that were not deleterious following *in silico* prediction using PolyPhen-2, SIFT or MutationTaster, were also deleted. The variants that were causing abnormal splicing or amino acid changes (including stop-loss and stop-gain variants), in particular those with minor allele frequencies (MAFs)  $<1\%$ , were recorded as possible candidates of the causative mutations. In view of the intractable and marked hypercholanemia observed in the patient, a panel of genes that may uniquely affect bile acid homeostasis were assembled for candidate mutation analysis using PubMed, The Online Mendelian Inheritance in Man record and primarily by reference to previous publications (12-16).

In summary, variation pathogenicity was analyzed using *in silico* methods of prediction using a number online tools. Next, the phenotypic features, including the genetic pattern of the genes involved in harboring pathogenic variations, were compared against the clinical and laboratory findings in the patient. Variations that were identified as causing cholestasis or affecting bile acid homeostasis were considered as being involved in affecting the phenotype of the patient.

## Results

**Case report.** A 6-month-old male infant was admitted to the First Affiliated Hospital of Jinan University as a result of elevated

serum total bile acid (TBA) discovered 4 months previously. At the age of 2 months, the patient underwent a liver function test due to mild jaundice, and it was observed that the levels of TBA and direct bilirubin were elevated. No steatorrhea or acholic stool was observed. After 1 month, the direct bilirubin level recovered gradually; however, the TBA remained elevated for 4 months. The infant was delivered by cesarean section at the gestation age of 38 weeks and 2 days (weight, 3.6 kg; body length, 50 cm) due to entanglement of the umbilical cord. The infant's parents were clinically and biochemically healthy with no family history of genetic disease.

The patient underwent a physical examination at 6 months (body weight, 8.5 kg; height, 71 cm; head circumference, 44.5 cm) and no dysmorphic appearance or jaundice was observed in the skin and sclera. No stridor, crackles or crepitus was heard with auscultation of the two lungs. The heart sound was normal without any murmurs. The liver and spleen were non-palpable. When picking the infant up, the tone of the body and limbs appeared normal. On biochemical analysis, the levels of TBA reached  $492.8 \mu\text{mol/l}$  ( $0-10 \mu\text{mol/l}$ ), whereas other indices were normal (Table II). Since citrin deficiency is a common etiology of infant cholestasis in Chinese, genetic analysis of the causative gene, SLC25A13, was performed; however, no mutations were observed, thus eliminating the possibility of citrin deficiency.

During the subsequent 2 years, itchy maculopapular rashes occurred occasionally in the trunk and extremities, and these were attributed to mite dermatitis. This conclusion was reached as serum IgE reached 1,460 IU/ml ( $0-60$ ), the serum antigens of *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae* were strongly positive, and anti-mite measures were able to effectively relieve the severity and frequency of the rash. His TBA reached a surprisingly high level of  $737.8 \mu\text{mol/l}$  at the age of 24.5 months (Table II). Therefore, it was concluded that the pruritus was allergic, not cholestatic, in the patient. Although a low serum level of total 25-OH vitamin D [ $21.4 \text{ ng/ml}$  ( $30-100$ )] at the age of 2 years and 7 months indicated vitamin D insufficiency, no obvious clinical presentations of fat soluble vitamin malabsorption were observed. The patient's anthropometric indices and social performance developed well without any symptoms or signs of hypotonia, delayed motor milestones and growth retardation on clinical follow-up. However, the hypercholanemia was marked and intractable, regardless of the introduction of cholestyramine at the age of 13 months. Therefore, at 30.5 months, SLC10A1 analysis was performed to evaluate the possibility of NTCP deficiency.

**SLC10A1 genotypes and variation frequency.** Sanger sequencing of the SLC10A1 gene demonstrated that the patient was a homozygote of the variation c.800C>T (p.Ser267Phe), and that both parents were carriers of the variation. A novel RFLP procedure was developed that confirmed the SLC10A1 genotype of the patient and his parents (Fig. 1). Screening for the p.Ser267Phe variation in the 75 control subjects was performed using the RFLP procedure, revealing 5 heterozygous carriers and 1 homozygote, who was a 30-year-old female without any positive symptoms or signs of NTCP but with a slightly elevated level of TBA [ $19.3 \mu\text{mol/l}$  ( $0-10 \mu\text{mol/l}$ )]. A 4.7% (7/150) allele frequency within the 75 volunteers indicated that the p.Ser267Phe variation is an SLC10A1 SNP.

Table II. Biochemical indices over time in a patient with marked hypercholanemia.

Indices (reference range)	Months									
	2	3	4	5	6 <sup>a</sup>	8.5	13 <sup>b</sup>	19	24.5	30.5
ALT (5-40 U/l)	33	30	37	31	32	34	27	24	16	17
AST (5-40 U/l)	49	32	37	38	37	36	41	37	31	36
GGT (8-50 U/l)	220	68	28	11	11	8	9	9	9	9
ALP (20-500 U/l)	383	345	317	273	236	332	270	248	254	247
Tbil (2-19 $\mu$ mol/l)	133.5	30.5	10.9	7.2	9.6	9.4	8.4	7.3	12.0	9.3
Dbil (0-6 $\mu$ mol/l)	98.4	23.0	7.6	4.5	6.0	4.8	4.7	4.2	5.8	4.9
Ibil (2.56-20.9 $\mu$ mol/l)	35.1	7.5	3.3	2.7	3.5	4.6	3.7	3.1	6.2	4.4
TBA (0-10 $\mu$ mol/l)	221.9	151.4	431.4	251.5	492.8	567.8	653.1	494.5	737.8	405.8

<sup>a</sup>First admission to hospital. <sup>b</sup>Cholestyramine was introduced. Each TBA value indicates severe hypercholanemia. ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase; Tbil, total bilirubin; Dbil, direct bilirubin; Ibil, indirect bilirubin; TBA, total bile acids.




Figure 1. Solute carrier family 10 member 1 (SLC10A1) genotypes in the family of the pediatric patient and the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) protocol for variation screening. (A) Sanger sequencing revealing that the pediatric patient is a homozygote whose parents are both carriers of the c.800C>T (p.Ser267Phe) variation. The SLC10A1 genotypes in the family were further confirmed by (B) gel electrophoresis using a newly-developed PCR-RFLP protocol, (C) the schematic diagram of which is illustrated. The variation generated a new digestive site for the restriction enzyme *HphI*, producing fragments of 65 and 164 bp from the 229 bp fragment from enzymatic digestion. bp, base pairs.

**Bioinformatics.** As presented in Fig. 2, the amino acid residue p.267Ser in human NTCP is relatively conserved among aligned homologous peptides from a number of species. SIFT analysis indicated that the c.800C>T (p.Ser267Phe) variation

was predicted to be 'deleterious' (SIFT score, 0.01). Using PolyPhen-2 software, a probability score of 0.959 was calculated, indicating that the variation is 'probably damaging'. Meanwhile, MutationTaster evaluation concluded that the variation is 'disease-causing' (probability value, 0.911).

**NGS results.** NGS analysis revealed 85 splicing, 80 stop-gain/stop-loss and 10,490 exonic nonsynonymous SNPs, and 586 exonic indels and 76 exonic SVs were detected. Among the NGS analysis results, 239 exonic nonsynonymous SNPs and 4 stop-gains with MAF <1% were detected that were 'benign' or 'tolerated' on functional prediction, and not associated with the clinical and biochemical features of the patient.

The bioinformatic tools PolyPhen-2, MutationTaster and SIFT, did not detect any 'deleterious' or 'damaging' variations among the NGS data of the 93 genes which were associated with inherited infantile cholestatic disorders (16). When focusing on the 51 genes that affect bile acid homeostasis uniquely, only 12 exonic nonsynonymous SNPs were detected (Table III). Aside from the p.S267F variation (rs2296651), none of the variations were predicted, clinically or bioinformatically, to be the causative variation of hypercholanemia in the patient. Consequently, the biallelic dysfunctional p.S267F variation in the SLC10A1 gene was concluded to be the unique determinant causing NTCP deficiency in the patient.

## Discussion

Vaz *et al* (7) first reported a patient with NTCP deficiency, who presented with extremely elevated TBA levels ( $\leq 1,500 \mu$ M, reference range,  $<16.3 \mu$ M) but otherwise a relatively mild clinical phenotype characterized by mild hypotonia, growth retardation and delayed motor milestones. The patient in the present case report presented with intractable and marked hypercholanemia with normal anthropometric development and social performance. The unique disturbance in bile salt homeostasis suggested that NTCP was the most likely affected molecule in the patient. A homologous p.Ser267Phe variation in the SLC10A1 gene was detected using Sanger sequencing, and orthologue alignment and pathogenicity prediction supported



Table III. Nonsynonymous exonic SNPs detected in genes that may affect bile acid homeostasis.

No.	Gene	OMIM ID	Location	dbSNP detected	Amino acid changes	Status
01	ATP8B1	602397	18q21.31			
02	ABCB11	603201	2q31.1	rs2287622	p.V444A	Heterozygous
03	TJP2	607709	9q21.11			
04	VPS33B	608552	15q26.1	rs11073964	p.G487S	Homozygous
05	VIPAS39	613401	14q24.3			
06	CCBE1	235510	18q21.32			
07	AMACR	604489	5p13.2	rs3195676	p.V9M	Heterozygous
08	CYP7A1	118455	8q12.1			
09	AKR1D1	604741	7q33			
10	HSD3B7	607764	16p11.2			
11	CYP7B1	603711	8q12.3			
12	CYP27A1	606530	2q35			
13	SLC27A5	603314	19q13.43			
14	BAAT	602938	9q31.1			
15	HSD17B4	601860	5q23.1	rs11205	p.I541V	Homozygous
16	SLC25A13	603859	7q21.3			
17	SERPINA1	107400	14q32.13			
18	BCS1L	603647	2q35			
19	ABCB4	171060	7q21.12			
20	CLDN1	603718	3q28			
21	JAG1	601920	20p12.2			
22	NOTCH2	600275	1p12-p11			
23	CFTR	602421	7q31.2			
24	Cirhin	604901	16q22.1			
25	SLC10A2 (ABST)	613291	13q33.1	rs188096	p.S171A	Heterozygous
26	EPHX1	132810	1q42.12			
27	NTCP (SLC10A1)	182396	14q24.2	rs2296651	p.S267F	Homozygous
28	ABCC2 (MRP2)	237500	10q24.2	rs17222589		
29	SLCO1B3	605495	12p12.2			
30	SLCO1B1	604843	12p12.2-p12.1			
31	MRP6 (ABCC6)	603234	16p13.11			
32	ABCG5	605459	2p21	rs6756629	p.R50C	Heterozygous
33	ABCG8	605460	2p21	rs6544718	p.V632A	Homozygous
34	SLCO2B1	604988	11q13.4	rs2306168	p.S342F	Heterozygous
35	SLCO1A2	602883	12p12.1			
36	SLCO4A1	612436	20q13.33			
37	SLC51A (OST $\alpha$ )	612084	3q29			
38	SLC51B (OST $\beta$ )	612085	15q22			
39	TMEM30A	611028	6q14.1			
40	TMEM30B	611029	14q23.1			
41	TMEM30C	611030	3q12.1			
42	NR1H4	603826	12q23.1			
43	CYP8B1	602172	3p22.1	rs9865715	p.S88P	Homozygous
44	SLC4A2	109280	7q36.1			
45	SLC10A7	611459	4q31.2			
46	SLC22A1 (OCT-1)	602607	6q25.3	rs628031	p.M408V	Homozygous
47	SLC22A7 (OAT-2)	604995	6p21.1			
48	MDR1 (ABCB1)	171050	7q21.12			
49	MRP3 (ABCC3)	604323	17q21.33			
50	MRP4 (ABCC4)	605250	13q32.1			
51	SLC47A1 (MATE-1)	609832	17p11.2			

Empty cells in this table denoted that no nonsynonymous exonic SNPs were detected in the relevant genes. OMIM ID, Online Mendelian Inheritance in Man identification; SNP, single nucleotide polymorphism; dbSNP, The SNP Database.

Species	Peptide ID	From	Amino acid sequence	To
Human NTCP-1	ENSP00000216540	248	RCRRTVSMETGCQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQVGEGLLL	300
Human ASBT	ENSP00000245312	252	YRCRTVAFETGMQNTQLCSTIVQLSFTPEELNVVTFPLIYSIFQLAAIF	304
Gorilla	ENSGGOP00000022961	250	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	302
Orangutan	ENSPYP00000006762	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Olive baboon	ENSPANP00000017171	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Gibbon	ENSNLEP00000002065	242	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEFSX	294
Chimpanzee	ENSPTRP00000010999	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Macaque	ENSMUP00000029493	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Marmoset	ENSCJAP00000027394	246	RCRRTVSMETGCQNVQLCSTILNGAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Vervet-AGM	ENSCSAP00000009215	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	298
Bushbaby	ENSGAP000000013546	248	RCRRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Elephant	ENSLAFP00000017315	251	QCRRTVSMETGCQNIQLCSTILNVTFPPEVIGPLFFFPFL--MIFIQGEGLLF	300
Panda	ENSAMEP00000015380	251	RCSRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	303
Horse	ENSECAP00000012659	248	RCRRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Cow	ENSBTAP00000002446	248	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Sheep	ENSOARP00000022773	248	RSKRTVSMETGCQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQVGEGLLL	300
Alpaca	ENSVPAP00000005985	248	RCSRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQVGEGLLL	300
Sloth	ENSCHOP00000004848	248	GCKRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Tree shrew	ENSBEP000000002346	248	QCSRTVSMETGCQNVQLCSTILNVTFRPEVIGPLFFFPFLYMIFQGEGLLL	300
Pig	ENSSSCP00000002511	248	RCSRTVCMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLF	300
Dog	ENSCAFP00000024409	248	RCSRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLF	300
Cat	ENSFCAP00000008204	248	RCRRTVSMETGCQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Shrew	ENSPVAP00000000978	248	RCRRTVSMETGCQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	300
Dolphin	ENSTTRP00000003115	252	HRCRTVALETGMQNTQLCSTIVQLSFTTEELNLTFTPLIYSIFQLIMAAIF	300
Opossum	ENSMODP00000014214	255	RCRRTVSMETGCQNIQLCSTILNMAFPPEEIGPLFFFPFLYMIFQGEGLLL	304
Rat	ENSRNOP00000007825	248	SCRRTISMETGFQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQLAEGLLI	307
Mouse	ENSMUSP000000093229	248	SCRRTISMETGFQNVQLCSTILNVTFPPEVIGPLFFFPFLYMIFQLAEGLLF	300
Squirrel	ENSSTOP00000003472	248	RCRRTISMETGFQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLF	300
Ferret	ENSMUPP00000007411	248	RCSRTVSMETGCQNVQLCSTILNVTFRPEVIGPLFFFPFLYMIFQGEGLLL	300
Armadillo	ENSDNOP00000004782	248	RGRRTVSMETGCQNVQLCATILNVTFPPEVIGPLFFFPFLYMIFQGEGLLF	300
Megabat	ENSFALP000000009265	248	XXCRHTVETGCQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQVAEGFLL	300
Microbat	ENSMUPP00000010888	251	RCRRTVSMETGCQNIQLCSTILNVTFPPEVIGPLFFFPFLYMIFQGEGLLL	303
Duck	ENSAPLP00000014650	256	QRSRTQVLQTPKLVQLCSTILKVAFAPEVIGPLFFFPFLYLMLFQL-----	308
Chicken	ENSGALP00000015323	248	RCRQTVMATGCQNVQLCSTILTVAFAPEVIGPLFFFPFLYLIFQGEGLLL	300
Flycatcher	ENSFALP000000005168	248	RCRRTVSMETGCQNVQLCSTILNVTFAPEVIGPLFFFPFLYLIFQGEGLLL	300
Softshell turtle	ENSPSIP00000000442	247	RCRRTVSMETGCQNVQLCSTILNVAFPPEVIGPLFFFPFLYMIFQGEGLLL	299
Turkey	ENSMGAP00000012582	244	HCRRTVSLETGCQNVQLCTAILKLTFPPLVGMVYMFPLLYALFQAAEAGLF	296
Cave fish	ENSAMXP00000012978	258	QCKRTIAVETGCQNIQLCSTILKVAFRPEVIGPLFFFPFLYIFQGEGLLF	312
Zebrafish	ENSARP000000113054	256	PCRRTVSMETGCQNIQLCSTILKVAFAPEVIGPLFFFPVYIVFQVIEALIF	308
Ciona intestinalis	ENSINP00000008688	224	NSRRTVAIETGCQNSQLSSTILKMAFANEVGMAYFLFP-LYALFQGLEGLAM	275

Figure 2. Alignment of homologous peptides in a diversity of species. With the exception of armadillo, turkey and zebrafish, all the remaining 37 species, including primates, rodents, laurasiatheria, placental mammals, sauropsida, fish and marine chordate, have the same serine residue as highlighted in green. This indicates that the p.Ser267Phe variation affected a number of conserved amino acid residues among species. NTCP, sodium taurocholate cotransporting polypeptide; ASBT, apical sodium-dependent bile acid transporter.

the disease-causing nature of this variation. In addition, the p.Ser267Phe variant was reported to exhibit a near complete loss of function of bile acid uptake, causing NTCP to lose its taurocholate transporting activity (5,17).

The experimental findings in the present study were similar to the functional analysis of the causative mutation p.Arg252His in the first patient that was reported to have NTCP deficiency, who was a homozygote of the causative mutation p.Arg252His (7). The p.Ser267Phe and p.Arg252His variations demonstrated similarly strong experimental and bioinformatic pathogenicity (5,7,17); using various *in silico* tools, the p.Arg252His mutation displayed a disease-causing nature with a score of 1.000 using PolyPhen-2, 0.9994 using MutationTaster and 0 using SIFT analysis. These results are similar to the functional predictions of the p.Ser267Phe SNP in the current study. Together, this evidences supports the diagnosis of NTCP deficiency in the patient in the present study.

As the genetic determinants of hypercholanemia are complex (16), whole genome sequencing was performed in the present study in order to evaluate the possible involvement of other genes, the collective testing of which was prohibitively

time-consuming and cost-expensive. The sequencing revealed that no other genetic mutations were causing perturbations of bile acid metabolism other than the SLC10A1 gene, and this further supports the diagnosis of NTCP deficiency in the patient. To the best of our knowledge, this is the second report of a patient with NTCP deficiency in the world.

The allele frequency of the p.Ser267Phe variation was calculated to be 4.7% in control subjects. This is consistent with previous studies which demonstrated that this polymorphism is common in East Asian countries including China and Vietnam, but not in European American, African American or Hispanic countries (4-6,18). NTCP is the functional receptor for human hepatitis B and D viruses (19). The p.Ser267Phe variation experimentally abrogates the ability of NTCP to support HBV infections in cell culture (17), and is associated with resistance to chronic hepatitis B in humans (18). This supports the concept that p.Ser267Phe SNP severely impairs the function of NTCP, and suggests that its high allele frequency may be a result of positive selection in Eastern Asia, where hepatitis B is more prevalent than in European American, African American or Hispanic countries (18).



Besides the NTCP-deficient biallelic p.Ser267Phe in the child patient in the present study, an adult homologous for the same dysfunctional SLC10A1 SNP was identified in the present study, who presented with slight hypercholanemia without other clinical or laboratory anomalies. The mechanism underlying the more prominent hypercholanemia in the infant, in comparison with the adult with the same SLC10A1 genotype, remains unknown. It is likely that the adult homozygote of the p.Ser267Phe SNP had, or lacked, a number of other genomic SNPs that were analyzed in the child (Table III). Another possible explanation is that the impaired NTCP function in the adult may have been compensated for by other transporters with the ability to uptake bile acids from the plasma, such as Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in the basolateral membrane of hepatocytes (20), and the type II form of microsomal epoxide hydrolase (21).

In addition to the prominent hypercholanemia, the elevated serum levels of ALT, AST, TBil and DBil in the child (Table II) suggested the presence of transient cholestasis in early infancy. The increased levels of GGT within the first 3 months after birth may have been partially attributed to cholestasis, although GGT activity is typically higher in infants than in adults (22). As the child was delivered by cesarean section due to entanglement of the umbilical cord, hypoxic ischemia of the liver may have been a likely cause for the transient elevation of the cholestatic indices. Another possibility is that the transient cholestatic liver disease experienced in early infancy may be a phenotypic feature of NTCP deficiency in the child. However, further research is required to determine whether liver disease is common in pediatric patients with NTCP deficiency.

In summary, the current study presents a pediatric patient who demonstrated prominent hypercholanemia with otherwise unremarkable presentations. SLC10A1 gene analysis revealed the presence of a p.Ser267Phe homozygote that is bioinformatically analyzed as a dysfunctional SNP that prevents the functioning of NTCP. Combined with the results from an adult with mild hypercholanemia, the diagnosis of the child with NTCP deficiency suggests, for the first time, that there is an association between the dysfunctional SNP and hypercholanemia. To the best of our knowledge, this is the second clinical description on NTCP deficiency worldwide.

## Acknowledgements

The authors thank Dr Qun-Zhou Zhang for the revision of the manuscript. The present study was supported by the National Natural Science Foundation of China (grant nos. 81270957 and 81570793) and the Cultivation Foundation for Scientific Research (grant no. 2014208) approved by the First Affiliated Hospital, Jinan University.

## References

- Hagenbuch B and Meier PJ: Molecular cloning, chromosomal localization, and functional characterization of a human liver Na<sup>+</sup>/bile acid cotransporter. *J Clin Invest* 93: 1326-1331, 1994.
- Hagenbuch B and Dawson P: The sodium bile salt cotransport family SLC10. *Pflugers Arch* 447: 566-570, 2004.
- Anwer MS and Stieger B: Sodium-dependent bile salt transporters of the SLC10A transporter family: More than solute transporters. *Pflugers Arch* 46: 77-89, 2014.
- Saito S, Iida A, Sekine A, Ogawa C, Kawauchi S, Higuchi S and Nakamura Y: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. *J Hum Genet* 47: 576-584, 2002.
- Ho RH, Leake BF, Roberts RL, Lee W and Kim BB: Ethnicity-dependent polymorphism in Na<sup>+</sup>-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. *J Biol Chem* 279: 7213-7222, 2004.
- Pan W, Song IS, Shin HJ, Kim MH, Choi YL, Lim SJ, Kim WY, Lee SS and Shin JG: Genetic polymorphisms in Na<sup>+</sup>-taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. *Xenobiotica* 41: 501-510, 2011.
- Vaz FM, Paulusma CC, Huidekoper H, de Ru M, Lim C, Koster J, Ho-Mok K, Bootsma AH, Groen AK, Schaap FG, *et al*: Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype. *Hepatology* 61: 260-267, 2015.
- Karpen SJ and Dawson PA: Not all (bile acids) who wander are lost: the first report of a patient with an isolated NTCP defect. *Hepatology* 61: 24-27, 2015.
- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS and Sunyaev SR: A method and server for predicting damaging missense mutations. *Nat Methods* 7: 248-249, 2010.
- Schwarz JM, Cooper DN, Schuelke M and Seelow D: MutationTaster2: Mutation prediction for the deep-sequencing age. *Nat Methods* 11: 361-362, 2014.
- Kumar P, Henikoff S and Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 4: 1073-1081, 2009.
- Boyer JL: Bile formation and secretion. *Compr Physiol* 3: 1035-1078, 2013.
- Hirschfield GM: Genetic determinants of cholestasis. *Clin Liver Dis* 17: 147-159, 2013.
- Marschall HU and Beuers U: When bile acids don't get amidated. *Gastroenterol* 144: 870-873, 2013.
- Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, Logan CV, Newbury LJ, Kamath BM, Ling S, *et al*: Mutations in TJP2 cause progressive cholestatic liver disease. *Nat Genet* 46: 326-328, 2014.
- Herbst SM, Schirmer S, Posovszky C, Jochum F, Rödl T, Schroeder JA, Barth TF, Hehr U, Melter M and Vermehren J: Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing. *Mol Cell Probes* 9: 291-29, 2015.
- Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J and Li W: Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. *J Virol* 88: 3273-3284, 2014.
- Peng L, Zhao Q, Li Q, Li M, Li C, Xu T, Jing X, Zhu X, Wang Y, *et al*: The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. *Hepatology* 61: 1251-1260, 2015.
- Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, *et al*: Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. *eLife* 1: e00049, 2012.
- Hagenbuch B and Meier PJ: The superfamily of organic anion transporting polypeptides. *Biochim Biophys Acta* 1609: 1-18, 2003.
- Zhu QS, Xing W, Qian B, von Dippel P, Schneider BL, Fox VL and Levy D: Inhibition of human m-epoxide hydrolase gene expression in a case of hypercholanemia. *Biochim Biophys Acta* 1638: 208-216, 2003.
- Cabrera-Abreu JC and Green A: Gamma-glutamyltransferase: Value of its measurement in paediatrics. *Ann Clin Biochem* 39: 22-25, 2002.